Ethoxidol [Ethylmethylhydroxypyridine Malate]

Formulation and packaging

1 tablet contains:

Active ingredients: ethylmethylhydroxypyridine malate 100 mg, N-Acetyl-DL-glutamic acid 68 mg, dimethylethanolamine 32 mg and glycine 20 mg;

Inactive ingredients: microcrystalline cellulose 206.1 mg, povidone 1.6 mg, lactose monohydrate 36 mg, pregelatinized starch 30 mg, fumed silica 9.5 mg, magnesium stearate 6 mg, croscarmellose sodium 12.8 mg, sodium cyclamate 18 mg and orange flavouring 6 mg.

1 pack contains 20 chewable tablets with 100 mg of the active ingredient. The pills have an orange flavor.

Application and dosage

Oral administration, chewable tablets.

As part of complex therapy of coronary heart disease, the recommended dosage is 1 tablet (100 mg) 3 times a day. The dosage can be gradually increased to obtain the therapeutic effect. The maximum single dose is 200 mg, the maximum daily dose is 800 mg. The minimum recommended treatment course is 2 months. The course can be repeated upon a doctor’s prescription. Individual duration of treatment course and dosage are to be prescribed by the doctor.

As part of complex therapy of mild or moderate cognitive impairment, the recommended dosage is 1 tablet (100 mg) 3-4 times a day with no limit to the duration of treatment.

Side effects

Ethoxidol is generally well tolerated. In rare cases, it can cause allergic reactions, dyspeptic disorders, nausea and dry mouth or diarrhea. The symptoms disappear on their own or upon the withdrawal of the drug. The prolonged drug administration can cause flatulence and sleep disorders.

Drug interaction

Ethoxidol enhances the effect of anticonvulsant drugs (carbamazepine), antiparkinson medication (levodopa) and benzodiazepine anxiolytics. It also re-duces the toxic effects of ethanol.


Overdose is unlikely due to low toxicity of Ethoxidol. If occurred, overdose can cause sleep disorders that are to be treated symptomatically.

Storage conditions

Store in a dark place at a temperature not higher than 25°C (77 °F). Keep out of the reach of children. Shelf life is 3 years.

Ethoxidol is a combination drug that inhibits free radical processes and has antioxidant, membrane-protective, anti-hypoxic, nootropic, anti-convulsant, anxiolytic and stress-protective effect. It contains ethylme-thylhydroxypyridine malate, which is a compound that is very closely related to another drug Mexidol. Ethoxidol was shown to be more effective than Mexidol in cardiac antiarhythmic effects, while other effects were very similar.

Apart from that it should be noted that Ethoxidol contains other active ingredients such as dimethylethanolamine (DMAE), N-Acetyl-DL-glutamic acid and glycine.

Ethoxidol can be used in anti-ischemic therapy as it stimulates blood flow in the penumbra. It also reduces total cholesterol and low-density lipoproteins.

The drug increases resistance towards various damaging factors, as well as pathological conditions such as shock, hypoxia, ischemia, cerebrovascular ac-cidents and intoxication with alcohol and antipsychotics (neuroleptics).

Ethoxidol improves brain metabolism, brain blood supply, microcirculation and blood's rheological properties and reduces platelet aggregation. It stabilizes membrane structures of erythrocytes and platelets that are involved in hemolysis.

Pharmacodynamic properties

Ethoxidol’s effect is driven by its antioxidant, anti-hypoxic and membrane-protective properties. It inhibits lipid peroxidation, increases the lipid-protein ratio, stabilizes the membrane fluidity and stimulates the membrane-bound enzymes and receptors.

Pharmacokinetic properties

After ingestion, the drug is absorbed from the gastrointestinal tract and gets distributed to the organs and tissues of the body. It stays in the blood plasma for 7-10 hours. Then Ethoxidol is extensively metabolized in the liver.


  • as part of complex therapy of coronary heart disease;
  • as part of complex therapy of ischemic stroke;
  • encephalopathy;
  • mild to moderate cognitive impairment.
  • Counterindications

    Hypersensitivity to the components of the drug, lactose intolerance, lactose deficiency, glucose galactose malabsorption, acute kidney injury, acute liver failure, children under 18 years of age, pregnancy and lactation.

    V Bekhterev (2016) An experimental in vitro study of antioxidant and antiradical properties of cytoflavin, vinpocetine, actovegin and ethylmethylhydroxypyridine succinate

    Type: Unknown Type